Current Perspectives and Future Directions in the Immunogenicity Landscape of Norovirus Vaccines

Human norovirus (HuNoV) is a leading cause of acute gastroenteritis worldwide, causing severe illness and death in vulnerable populations, including infants and the elderly. Despite advances in norovirus vaccine candidates such as virus-like particles (VLPs), adenovirus-based oral vaccines, and mRNA vaccines, no vaccine has been approved yet. Current clinical trials primarily target the GI.1 and GII.4 genotypes responsible for most outbreaks. However, the extensive genetic diversity of HuNoV, along with continual antigenic evolution, poses significant challenges for developing broadly protective vaccines. Recent advances in experimental tools, including human intestinal enteroid cultures and surrogate neutralization assays, have improved norovirus vaccine efficacy assessment. Nevertheless, the lack of robust culture systems and animal models that faithfully mimic human infection continues to limit comprehensive evaluation of immune responses to diverse variants. Moreover, standardized correlates of protection, particularly those addressing mucosal immunity critical for infection prevention, remain to be established. This review integrates current immunogenicity assessment methodologies and evaluates ongoing HuNoV vaccine strategies, with emphasis on variant strain selection and platform technologies. We discuss key challenges related to population diversity, immune imprinting, and the complex interplay between systemic and mucosal immune responses as influenced by vaccine delivery routes and adjuvant formulations. By integrating recent advances in vaccine platforms, immunological tools, and delivery strategies, this review provides a framework for addressing critical obstacles in norovirus vaccine development. Such integrative perspectives are crucial for developing safe, effective, and broadly protective vaccines that offer meaningful benefits to global health.

• Publication year

  2025

• Venue

  Journal of Microbiology and Biotechnology

• Publication date

  2025-11-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4014/jmb.2509.09003PMID 41218799PMCID 12634205
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial

  2025cited by this paper
• Epidemiology and genetic diversity of norovirus GII genogroups among pediatric patients in Beijing, China, during 2023–2024

  2025cited by this paper
• Increasing Predominance of Norovirus GII.17 over GII.4, United States, 2022–2025

  2025cited by this paper
• An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study.

  2025cited by this paper
• Gut microbiota modulate immune responses to orally and parenterally administered rotavirus in mice

  2025cited by this paper
• Ionizable lipid nanoparticles of mRNA vaccines elicit NF-κB and IRF responses through toll-like receptor 4

  2025cited by this paper
• The advent of clinical self-amplifying RNA vaccines.

  2025cited by this paper
• An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial.

  2025cited by this paper
• Broadly neutralizing antibodies targeting pandemic GII.4 variants or seven GII genotypes of human norovirus.

  2025cited by this paper
• Genomic diversity and comparative phylogenomic analysis of genus Norovirus

  2025cited by this paper
• Vaccinia Virus Vector Bivalent Norovirus Vaccine

  2025cited by this paper
• 220. A Phase 2 Double-Blind, Placebo-Controlled Study Showing Oral Tableted Norovirus Vaccine VXA-G1.1-NN is Immunogenic, Efficacious, and Reduces Viral Shedding Following Norovirus Challenge

  2025cited by this paper
• Insights into human norovirus cultivation in human intestinal enteroids

  2024cited by this paper
• Systematic review of the impact of intestinal microbiota on vaccine responses

  2024cited by this paper
• Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9- and type I IFN-dependent pathway

  2024cited by this paper
• In Vitro Culture of Human Norovirus in the Last 20 Years

  2024cited by this paper
• Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023

  2024cited by this paper
• Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection

  2024influential reference
• Increased circulation of GII.17 noroviruses, six European countries and the United States, 2023 to 2024

  2024cited by this paper
• GI.1 Norovirus Neutralizing Antibody Levels Are Correlated with GI.1 Histo-blood Group Antigen-Blocking Antibody Levels.

  2024cited by this paper
• Noroviruses: Evolutionary Dynamics, Epidemiology, Pathogenesis, and Vaccine Advances—A Comprehensive Review

  2024cited by this paper
• A narrative review of norovirus epidemiology, biology, and challenges to vaccine development

  2024cited by this paper
• Human norovirus cultivation systems and their use in antiviral research

  2024influential reference
• Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial

  2023cited by this paper
• TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview

  2023cited by this paper
• Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen

  2023cited by this paper
• A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies.

  2023cited by this paper
• SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies

  2023cited by this paper
• Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

  2023influential reference
• Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses

  2023cited by this paper
• Recent insights into reverse genetics of norovirus

  2023cited by this paper
• Lactobacillus salivarius HHuMin-U Activates Innate Immune Defense against Norovirus Infection through TBK1-IRF3 and NF-κB Signaling Pathways

  2022cited by this paper
• Intranasal COVID-19 vaccines: From bench to bed

  2022cited by this paper
• Gastrointestinal organoids in the study of viral infections

  2022cited by this paper
• A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

  2022cited by this paper
• SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals

  2022cited by this paper
• Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants.

  2022cited by this paper
• Norovirus: An Overview of Virology and Preventative Measures

  2022cited by this paper
• Breadth and Dynamics of Human Norovirus-Specific Antibodies in the First Year of Life

  2022cited by this paper
• Enteric viruses replicate in salivary glands and infect through saliva

  2022cited by this paper
• 6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice

  2022cited by this paper
• Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines

  2021cited by this paper
• Understanding the relationship between norovirus diversity and immunity

  2021cited by this paper
• Norovirus-Specific CD8+ T Cell Responses in Human Blood and Tissues

  2021cited by this paper
• Norovirus Vaccines: Current Clinical Development and Challenges

  2021cited by this paper
• Predicted norovirus resurgence in 2021–2022 due to the relaxation of nonpharmaceutical interventions associated with COVID-19 restrictions in England: a mathematical modeling study

  2021cited by this paper
• Norovirus Outbreak amid COVID-19 in the United Kingdom; Priorities for Achieving Control.

  2021cited by this paper
• Association of fucosyltransferase 2 gene with norovirus infection: A systematic review and meta-analysis.

  2021cited by this paper
• Emerging concepts in the science of vaccine adjuvants

  2021cited by this paper
• Humoral and Mucosal Immune Responses to Human Norovirus in the Elderly.

  2020cited by this paper
• Clinical significance of the fucosyltransferase 2 (FUT2) secretor status in children hospitalized with acute gastroenteritis in Taiwan.

  2020cited by this paper
• Algorithm for optimized mRNA design improves stability and immunogenicity

  2020cited by this paper
• Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response

  2020cited by this paper
• Norovirus-specific immunoglobulin A in breast milk for protection against norovirus-associated diarrhea among infants.

  2020cited by this paper
• FUT2, Secretor Status and FUT3 Polymorphisms of Children with Acute Diarrhea Infected with Rotavirus and Norovirus in Brazil

  2020cited by this paper
• Antiviral efficacy of orally delivered neoagarohexaose, a nonconventional TLR4 agonist, against norovirus infection in mice.

  2020cited by this paper
• Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults.

  2020cited by this paper
• Norovirus Vaccine: Priorities for Future Research and Development

  2020cited by this paper
• A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose.

  2020cited by this paper
• Recent advances in human norovirus research and implications for candidate vaccines

  2020cited by this paper
• ICTV Virus Taxonomy Profile: Caliciviridae

  2019cited by this paper
• Human Norovirus: Experimental Models of Infection

  2019cited by this paper
• The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine

  2019cited by this paper
• Virus Like Particles of GII.4 norovirus bind Toll Like Receptors 2 and 5.

  2019cited by this paper
• Updated classification of norovirus genogroups and genotypes.

  2019cited by this paper
• Enhanced GII.4 human norovirus infection in gnotobiotic pigs transplanted with a human gut microbiota.

  2019cited by this paper
• Hepatic tristetraprolin promotes insulin resistance through RNA destabilization of FGF21.

  2018cited by this paper
• Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial.

  2018influential reference
• Prophylactic efficacy of orally administered Bacillus poly-γ-glutamic acid, a non-LPS TLR4 ligand, against norovirus infection in mice

  2018cited by this paper
• Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients

  2018cited by this paper
• More robust gut immune responses induced by combining intranasal and sublingual routes for prime-boost immunization

  2018cited by this paper
• Pathogenesis of human norovirus genogroup II genotype 4 in post-weaning gnotobiotic pigs.

  2018cited by this paper
• Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice

  2018cited by this paper
• Human Norovirus Neutralized by a Monoclonal Antibody Targeting the Histo-Blood Group Antigen Pocket

  2018cited by this paper
• Pathogenesis of Human Norovirus Genogroup II Genotype 4 in Post-Weaning Gnotobiotic Pigs.

  2018cited by this paper
• B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine

  2017cited by this paper
• Norovirus Infection in Older Adults: Epidemiology, Risk Factors, and Opportunities for Prevention and Control.

  2017cited by this paper
• Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016

  2017cited by this paper
• Differentiation and Protective Capacity of Virus‐Specific CD8+ T Cells Suggest Murine Norovirus Persistence in an Immune‐Privileged Enteric Niche

  2017cited by this paper
• Human intestinal organoids express histo-blood group antigens, bind norovirus VLPs, and support limited norovirus replication

  2017cited by this paper
• Gut memories do not fade: epigenetic regulation of lasting gut homing receptor expression in CD4+ memory T cells

  2017cited by this paper
• Norovirus-Specific Memory T Cell Responses in Adult Human Donors

  2016cited by this paper
• Human norovirus transmission and evolution in a changing world

  2016cited by this paper
• Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding

  2016cited by this paper
• Host Genetic Susceptibility to Enteric Viruses: A Systematic Review and Metaanalysis.

  2016cited by this paper
• Correlates of Protection against Norovirus Infection and Disease—Where Are We Now, Where Do We Go?

  2016cited by this paper
• Persistence and Elimination of Human Norovirus in Food and on Food Contact Surfaces: A Critical Review.

  2016cited by this paper
• Norovirus vaccines: Correlates of protection, challenges and limitations

  2016cited by this paper
• A Gnotobiotic Pig Model for Determining Human Norovirus Inactivation by High-Pressure Processing

  2015cited by this paper
• Mucosal and Cellular Immune Responses to Norwalk Virus.

  2015cited by this paper
• Norovirus

  2015cited by this paper
• Norovirus immunology: Of mice and mechanisms

  2015cited by this paper
• Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.

  2015cited by this paper
• Human norovirus culture in B cells

  2015cited by this paper
• Norovirus gene expression and replication.

  2014cited by this paper
• Enteric bacteria promote human and mouse norovirus infection of B cells

  2014cited by this paper
• Determination of the 50% human infectious dose for Norwalk virus.

  2014cited by this paper
• Plasmid-based human norovirus reverse genetics system produces reporter-tagged progeny virus containing infectious genomic RNA

  2014cited by this paper
• The state of norovirus vaccines.

  2014cited by this paper
• A Mouse Model for Human Norovirus

  2013cited by this paper

• No citing papers are available for this paper.